Bayesian Capital Management’s CareDx CDNA Stock Holding History

Bayesian Capital Management’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,700	Closed	-$225K	–	583
2025 Q1	$225K	Buy	+12,700	New	+$274K	0.04%	462
2024 Q4	–	Sell	-21,333	Closed	-$666K	–	718
2024 Q3	$666K	Buy	+21,333	New	+$531K	0.08%	317
2023 Q4	–	Sell	-21,000	Closed	-$147K	–	780
2023 Q3	$147K	Buy	+21,000	New	+$194K	0.02%	578
2021 Q2	–	Sell	-5,900	Closed	-$402K	–	439
2021 Q1	$402K	Buy	+5,900	New	+$458K	0.09%	278
2019 Q4	–	Sell	-19,466	Closed	-$440K	–	608
2019 Q3	$440K	Buy	+19,466	New	+$539K	0.08%	303
2019 Q1	–	Sell	-20,600	Closed	-$518K	–	573
2018 Q4	$518K	Buy	20,600 +8,000	+63%	+$206K	0.11%	279
2018 Q3	$364K	Sell	12,600 -2,500	-17%	-$46.8K	0.06%	403
2018 Q2	$185K	Buy	+15,100	New	+$173K	0.04%	528

Other funds holding CDNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAM

Ophir Asset Management Sydney, Australia $859M AUM 59.08% 1-Year Est. Return

Bayesian Capital Management's CDNA Position: Q2 2025 in Review

Bayesian Capital Management sold out of CareDx (CDNA) in Q2 2025, closing a stake of 12,700 shares — an estimated $225K sold.

Bayesian Capital Management first reported a position in CDNA in Q2 2018 and held it in 8 quarters. The position peaked at $666K in Q3 2024. 197 funds tracked by Wall St. Rank hold CDNA as of Q2 2025.

Bayesian Capital Management reported no remaining CareDx position as of Q2 2025 after selling out during the quarter.
Bayesian Capital Management sold 12,700 CareDx shares in Q2 2025, an estimated $225K.
Bayesian Capital Management first reported a position in CareDx in Q2 2018 and held it in 8 quarters.
Bayesian Capital Management's CareDx position peaked at $666K in Q3 2024.
197 funds tracked by Wall St. Rank held CareDx as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.